The scientific goal of the Hollings Cancer Center (HCC) Developmental Cancer Therapeutics (DCT) Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of principle, early phase clinical and correlative science studies. The DCT Program is co-led by Kenneth D. Tew, PhD and Carolyn D. Britten, MD. The DCT Program is organized around three themes of scientific investigation: ? Elucidation of Cellular Signaling Pathways. ? Modulation of Redox and Cellular Stress Response. ? Development of Small Molecule Chemotherapeutic Agents. The 46 members of the DCT Program, representing 12 departments within the College of Medicine and the College of Pharmacy, have 87 active grants/contracts totaling $11.7M in cancer research funding ($7.7 in peer-reviewed funding and $3.7M from the NCI). In 2012 the DCT Program implemented 65 early phase (pilot. Phase I, Phase l/ll, and Phase II) interventional treatment clinical trials, of which 25 were invesfigator initiated;224 patients were enrolled onto all DCT Program interventional treatment studies. In the past five years, DCT Program members produced 305 cancer-focused publications with 17% of these representing inter-programmatic and 35% intra-programmatic collaborations and 48% from mulfi-insfitutional collaborations.

Public Health Relevance

Members of the Developmental Cancer Therapeutics Program are linked by synergistic research interests with a focus on drug discovery and development. Collaborations between this program's clinical and laboratory investigators are leading to development of new clinical cancer trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA138313-06
Application #
8695806
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-01
Project End
2019-03-31
Budget Start
2014-06-20
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$30,754
Indirect Cost
$10,213
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Barton, Virginia; Armeson, Kent; Hampras, Shalaka et al. (2017) Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review. Arch Dermatol Res 309:243-251
Alexander-Bryant, Angela A; Zhang, Haiwen; Attaway, Christopher C et al. (2017) Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo. Oral Oncol 72:123-131
Kim, Sungjin; Alsaidan, Omar Awad; Goodwin, Octavia et al. (2017) Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res 77:6950-6962
Yang, Aimin; Qin, Shenghui; Schulte, Bradley A et al. (2017) MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer. Cancer Res 77:6641-6650
Karam, Joseph A; Parikh, Rasesh Y; Nayak, Dhananjaya et al. (2017) Co-chaperone Hsp70/Hsp90-organizing protein (Hop) is required for transposon silencing and Piwi-interacting RNA (piRNA) biogenesis. J Biol Chem 292:6039-6046
Mehrotra, Shikhar; Britten, Carolyn D; Chin, Steve et al. (2017) Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol 10:82
Sagar, Amin; Arif, Ehtesham; Solanki, Ashish Kumar et al. (2017) Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function. Sci Rep 7:12047
Liu, Qinlong; Rehman, Hasibur; Krishnasamy, Yasodha et al. (2017) 8-pCPT-cGMP prevents mitochondrial depolarization and improves the outcome of steatotic partial liver transplantation. Int J Physiol Pathophysiol Pharmacol 9:69-83
Ghatak, Shibnath; Hascall, Vincent C; Markwald, Roger R et al. (2017) Transforming growth factor ?1 (TGF?1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis. J Biol Chem 292:10490-10519
Lemasters, John J (2017) Evolution of Voltage-Dependent Anion Channel Function: From Molecular Sieve to Governator to Actuator of Ferroptosis. Front Oncol 7:303

Showing the most recent 10 out of 369 publications